Ryman Healthcare Limited Ordinary Shares
RYM.NZXHealth Care
Ryman Healthcare limited (RYM) is the largest provider of retirement living options for New Zealanders over the age of 70. The company provides a range of retirement living and care options, including independent townhouses and apartments, serviced apartments and care centres providing resthome, dementia and hospital-level care. RYM was established in Christchurch in 1984. It was listed in June 1999 followed a public offering of 30 million shares at a price of $1.35. In January 2007 the company implemented a 5:1 share split. In 2014 RYM opened its first village in Melbourne and plans to build four more in Victoria by 2020. As at July 2016, RYMs 30 retirement villages in New Zealand and Australia provided homes for over 10,000 residents and employed more than 4,000 staff.
Market Data
$2.260
-0.0%$2.3B
-13.4x
$-0.169
0.00%
+0.0%
Latest Earnings
Ryman Healthcare reports 1H26 results
26 November 2025
Ryman Healthcare reported a net loss after tax of NZD $45.2 million for 1H26 (six months to 30 September 2025), a deterioration from the $82.0 million profit in 1H25, driven by significantly lower fair value movements on investment properties despite a meaningful improvement in underlying operating performance. Positively, the company achieved its first positive free cash flow in over a decade at $56.2 million (up $108.7 million), with total revenue growing 13% to $413.8 million and total costs falling 2%, reflecting the traction of cost-out initiatives. The balance sheet reset is now complete following a $2.0 billion bank refinancing, and FY26 sales guidance was upgraded to 1,300–1,400 ORAs alongside an increased annualised cost savings target of $50–60 million. Key points: First positive free cash flow in over a decade of $56.2 million, up $108.7 million on the prior corresponding period.; Total revenue grew 13% to $413.8 million driven by higher pricing and utilisation, while total costs fell 2% as cost-out initiatives gained traction.; Annualised cost savings achieved to date lifted to $40 million with FY26 target raised to $50–60 million from prior guidance of $46 million.
Recent Announcements
FY26 marks significant year of progress
Ryman Healthcare Limited reported its FY26 financial results for the year ended 31 March 2026, showing a net loss of NZD 171.3 million (compared to NZD 513.7 million loss in FY25) with revenue of NZD 855.6 million, reflecting operational improvements despite fair value property movements and ongoing investment in aged care and retirement village operations across New Zealand and Australia.
Ryman Healthcare appoints new independent director
Ryman Healthcare has appointed Hamish Rumbold as an independent non-executive director effective 1 May 2026, bringing expertise in digital, technology, and customer experience from previous roles at Kiwibank, Air New Zealand, and other organizations. This appointment completes the company's board refresh, and Rumbold will stand for re-election at the 2026 Annual Shareholders Meeting.
Fourth quarter trading update
Ryman Healthcare reported 331 retirement living sales in Q4 FY26 (up 10% year-on-year), with full-year FY26 sales of 1,410 occupation right agreements and expected free cash flow of approximately $180 million; net interest-bearing debt stood at $1.57 billion as of 31 March 2026.
FY26 full year results webcast details
Ryman Healthcare announced that its FY26 full year results for the twelve months to 31 March 2026 will be reported on Tuesday, 26 May 2026, with an investor and analyst briefing held via webcast at 11.00am NZT.
Amendments to Bond Trust Deed
Ryman Healthcare Limited amended its Master Trust Deed relating to senior secured bonds (NZX ticker RYM010) to update definitions of the Guaranteeing Group Coverage Covenant and related financial metrics (Adjusted EBITDA, Total Tangible Assets, etc.) to align with equivalent definitions in its bank facility agreement. The Supervisor (Public Trust) determined the amendments do not have a material adverse effect on bondholders and certified compliance with financial market regulations.
SPH Notice - Cooper Investors Pty Limited
Cooper Investors Pty Limited changed substantial holding from 4.9927% to 5.6287%.
2026 Investor Day Recording
Ryman Healthcare has made a recording of its 2026 Investor Day available online, where management discussed the company's refreshed strategy, new capital management framework and dividend policy.
Refreshed strategy and new capital management framework
Ryman Healthcare announced a refreshed strategy targeting $150 million in sustainable cash flow improvement by FY29 and $500 million in cash release, with plans to return to sustainable dividends in FY28 under a new capital management framework with a 20-50% payout policy.
Third quarter trading update
Ryman Healthcare reported 375 ORA sales in Q3 FY26 (375 total: 101 new, 274 resales), with sales broadly flat quarter-on-quarter despite mixed market conditions; the company maintained full-year FY26 guidance of 1,300-1,400 sales and noted improved contract conversion and reduced cancellation rates.
Ryman Healthcare reports 1H26 results
Ryman Healthcare reported a net loss after tax of NZD $45.2 million for 1H26 (six months to 30 September 2025), a deterioration from the $82.0 million profit in 1H25, driven by significantly lower fair value movements on investment properties despite a meaningful improvement in underlying operating performance. Positively, the company achieved its first positive free cash flow in over a decade at $56.2 million (up $108.7 million), with total revenue growing 13% to $413.8 million and total costs falling 2%, reflecting the traction of cost-out initiatives. The balance sheet reset is now complete following a $2.0 billion bank refinancing, and FY26 sales guidance was upgraded to 1,300–1,400 ORAs alongside an increased annualised cost savings target of $50–60 million. Key points: First positive free cash flow in over a decade of $56.2 million, up $108.7 million on the prior corresponding period.; Total revenue grew 13% to $413.8 million driven by higher pricing and utilisation, while total costs fell 2% as cost-out initiatives gained traction.; Annualised cost savings achieved to date lifted to $40 million with FY26 target raised to $50–60 million from prior guidance of $46 million.
Get real-time alerts for RYM
Receive AI-powered earnings summaries and instant notifications when Ryman Healthcare Limited Ordinary Shares releases results.
Register Free